The use of finasteride in reduction of prostate volume prior to brachytherapy treatment in low and intermediate risk prostate cancer

被引：0
|
作者：
Foran, A.
Foran, P.
McNicholas, M.
Maher, M.
机构：
[1] Mater Misericordiae Univ Hosp, Dept Radiol, Dublin, Ireland
[2] Mater Private Hosp, Dept Radiat Oncol, Dublin, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2017年 / 186卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
65
引用
收藏
页码：S138 / S138
页数：1
相关论文
共 50 条
  • [1] Reduction in the risk of prostate cancer with finasteride
    Vanessa Marchesi
    Nature Reviews Clinical Oncology, 2013, 10 (11) : 608 - 608
  • [2] EFFECTIVENESS OF BICALUTAMIDE AND DUTASTERIDE FOR PROSTATE VOLUME REDUCTION PRIOR TO PROSTATE BRACHYTHERAPY
    Wong, J.
    Sylvester, J.
    Takamiya, R.
    Eulau, S.
    Khanjian, J.
    Grimm, P.
    RADIOTHERAPY AND ONCOLOGY, 2009, 92 : S60 - S61
  • [3] Permanent prostate brachytherapy for intermediate risk prostate cancer
    Frazier, AJ
    Keole, SR
    Forman, JD
    Cher, M
    Zuniga, C
    Rosemberg, S
    RADIOLOGY, 2002, 225 : 266 - 267
  • [4] HDR brachytherapy as monotherapy for low and intermediate risk prostate cancer
    Gaudet, M.
    Pharand-Charbonneau, M.
    Wright, D.
    Desrosiers, M.
    Haddad, A.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S1188 - S1188
  • [5] HDR MONO-BRACHYTHERAPY FOR LOW AND INTERMEDIATE RISK CANCER OF THE PROSTATE
    Johansson, B.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S214 - S214
  • [6] High-dose-rate brachytherapy as a monotherapy in the treatment of low and intermediate risk prostate cancer
    Ghadjar, P.
    Keller, T.
    Rentsch, C. A.
    Isaak, B.
    Behrensmeier, F.
    Stroux, A.
    Thalmann, G. N.
    Aebersold, D. M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 : 43 - 44
  • [7] Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer
    Detti, B.
    Bonomo, P.
    Masi, L.
    Doro, R.
    Cipressi, S.
    Iermano, C.
    Bonucci, I.
    Franceschini, D.
    Di Cataldo, V.
    Di Brina, L.
    Baki, M.
    Simontacchi, G.
    Meattini, I.
    Carini, M.
    Serni, S.
    Nicita, G.
    Livi, L.
    CANCER INVESTIGATION, 2015, 33 (05) : 188 - 192
  • [8] Low and intermediate risk prostate cancer: Treatment options
    Minana-Lopez, Bernardino
    Reina-Alcaina, Leandro
    Rivero-Guerra, Angela
    Rosino-Sanchez, Antonio
    Izquierdo-Morejon, Emilio
    Pietricica, Bogdan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (06): : 260 - 270
  • [9] Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
    Kunogi, Hiroaki
    Wakumoto, Yoshiaki
    Kawamoto, Terufumi
    Oshima, Masaki
    Horie, Shigeo
    Sasai, Keisuke
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (06) : 554 - 561
  • [10] Prostate mono brachytherapy (I-125) is an effective treatment option for low intermediate risk Gleason 7 prostate cancer
    Zippe, C.
    Pahlajani, G.
    Phillippi, A.
    Ochoa, R.
    Mahadevan, A.
    Ciezki, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S315 - S316
12345